Evidence map›Paper›PMID 36421832›Full record

ArticleGenes2022

Extracellular Vesicle MicroRNA in Malignant Pleural Effusion.

Samira Shojaee, Giulia Romano, Trinidad M Sanchez, Gulmira Yermakhanova, Michela Saviana, Patricia Le, Giovanni Nigita, Federica Calore, Rachel Guthrie, Kathryn Hess and 6 more

Open access · goldAbstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Samira ShojaeeVanderbilt University Medical Center, Department of Internal Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, 1301 Medical Center Drive, Suite B187, Nashville, TN 37232, USA.
Giulia RomanoVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Trinidad M SanchezVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Gulmira YermakhanovaVanderbilt University Medical Center, Department of Internal Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, 1301 Medical Center Drive, Suite B187, Nashville, TN 37232, USA.
Michela SavianaVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Patricia LeVanderbilt University Medical Center, Department of Internal Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, 1301 Medical Center Drive, Suite B187, Nashville, TN 37232, USA.ORCID 0000-0002-9344-1301
Giovanni NigitaDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-8880-4334
Federica CaloreDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.
Rachel GuthrieVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Kathryn HessVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Le KangVirginia Commonwealth University Health System, Department of Biostatistics, Richmond, VA 23298, USA.
Theresa Swift-ScanlanVirginia Commonwealth University School of Nursing, Richmond, VA 23298, USA.
Jacob T GrahamVirginia Commonwealth University School of Nursing, Richmond, VA 23298, USA.
Najib M RahmanOxford Respiratory Trials Unit, University of Oxford, Oxford NIHR Biomedical Research Centre, Oxford and Chinese Academy of Medical Sciences Oxford Institute, Oxford OX3 7LE, UK.
Patrick S Nana-SinkamVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Mario AcunzoVirginia Commonwealth University Health System, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Richmond, VA 23298, USA.
Virginia Commonwealth University · USVanderbilt University Medical Center · USThe Ohio State University · USChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Institutional Career Development CoreKL2TR002648 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI NANASINKAM, SERGE PATRICK, SANYAL, ARUN J · 2018 to 2022
$3.7M
Extracellular Vesicles in Small Cell Lung Cancer Early DetectionU01CA213330 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LEE, LY JAMES, NANASINKAM, SERGE PATRICK · 2017 to 2021
$2.7M
NCATS NIH HHS KL2 TR002648NCI NIH HHS U01 CA213330
6 · The paper itself

Abstract

Lung and breast cancer are the two most common causes of malignant pleural effusion (MPE). MPE diagnosis plays a crucial role in determining staging and therapeutic interventions in these cancers. However, our understanding of the pathogenesis and progression of MPE at the molecular level is limited. Extracellular Vesicles (EVs) and their contents, including microRNAs (miRNAs), can be isolated from all bodily fluids, including pleural fluid. This study aims to compare EV-miRNA patterns of expression in MPE caused by breast (BA-MPE) and lung (LA-MPE) adenocarcinomas compared to the control group of heart-failure-induced effusions (HF-PE). We conducted an analysis of 24 pleural fluid samples (8 LA-MPE, 8 BA-MPE, and 8 HF-PE). Using NanoString technology, we profiled miRNAs within EVs isolated from 12 cases. Bioinformatic analysis demonstrated differential expression of miR-1246 in the MPE group vs. HF-PE group and miR-150-5p and miR-1246 in the BA-MPE vs. LA-MPE group, respectively. This difference was demonstrated and validated in an independent cohort using real-time PCR (RT-PCR). miRNA-1246 demonstrated 4-fold increased expression (OR: 3.87, 95% CI: 0.43, 35) in the MPE vs. HF-PE group, resulting in an area under the curve of 0.80 (95% CI: 0.60, 0.99). The highest accuracy for differentiating MPE vs. HF-PE was seen with a combination of miRNAs compared to each miRNA alone. Consistent with prior studies, this study demonstrates dysregulation of specific EV-based miRNAs in breast and lung cancer; pleural fluid provides direct access for the analysis of these EV-miRNAs as biomarkers and potential targets and may provide insight into the underlying pathogenesis of tumor progression. These findings should be explored in large prospective studies.

Indexed as

Extracellular VesiclesLung NeoplasmsMicroRNAsPleural Effusion, MalignantHumansProspective StudiesMicroRNAsbreast cancerEV-miRNAextracellular vesicle microRNAlung cancermalignant pleural effusion

Identifiers

PMID36421832
PMCPMC9691121
OpenAlexW4309740600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.